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INTRODUCTION
Mycobacterium abscessus is the most pathogenic and chemo-
therapy-resistant rapidly growing mycobacteria (RGM). It
accounts for 80% of lung disease caused by RGM and is the
second most common RGM species present in extrapulmo-
nary disease (following M. fortuitum) (1-4).
M. abscessus is resistant to all antituberculosis drugs includ-
ing isoniazid, rifampin, ethambutol, and pyrazinamide. Thus,
routine susceptibility testing to antituberculosis drugs is not
recommended for this species. M. abscessus is considered to be
susceptible to amikacin, cefoxitin, and clarithromycin, and
moderately susceptible to imipenem (1-4). However, M. absces-
sus is not an easy organism to treat, and long-term treatment
with multiple antimicrobial agents is usually required. Some
studies have reported that in vitro susceptibilities to several
antimicrobial agents are correlated with clinical responses
to treatment in RGM infections (5, 6). Thus, drug suscepti-
bility tests are important for appropriate patient manage-
ment. In addition, all clinically significant isolates should
be tested against selected antimicrobial agents (1, 2).
In Korea, M. abscessus is the second most common etiolo-
gy of lung disease caused by nontuberculous mycobacteria
(NTM) (following the M. avium-intracellulare complex). It
accounts for 21 to 33% of NTM lung disease in Korea (7-9);
however, in vitro antimicrobial susceptibility test results for
this organism have never been investigated in Korean popu-
lation. Therefore, we examined the in vitro susceptibilities of
M. abscessus isolates from patient respiratory specimens that
displayed M. abscessus lung disease. 
MATERIALS AND METHODS
From July 2005 to December 2006, 74 nonduplicate iso-
lates of M. abscessus (one isolate per patient) recovered from
respiratory clinical samples were collected for use in this study.
NTM species identification was performed using the poly-
merase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) method based on the rpoB gene (10). All
patients met the diagnostic criteria recommended by the
American Thoracic Society for M. abscessus lung disease (11).
Antimicrobial susceptibility testing was performed at the
Korean Institute of Tuberculosis according to the guidelines
set forth by the National Committee for Clinical Laboratory
Standards (NCCLS) (12, 13). We tested eight antimicrobial
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Mycobacterium abscessus is the second most common etiology of pulmonary dis-
ease caused by nontuberculous mycobacteria in Korea. Although antimicrobial sus-
ceptibility tests are important for appropriate patient management in M. abscessus
lung disease, the tests have never been investigated in Korea. Seventy-four iso-
lates of M. abscessus recovered from patient respiratory samples were tested against
eight antimicrobial agents following the guidelines set forth by the National Commit-
tee for Clinical Laboratory Standards. Of the parenteral antibiotics, amikacin (99%,
73/74) and cefoxitin (99%, 73/74) were active against most isolates. Imipenem
(55%, 36/66) and tobramycin (36%, 27/74) had activity against moderate number
of isolates. Of the oral antibiotics, clarithromycin (91%, 67/74) was active against
the majority of isolates. Moxifloxacin (73%, 54/74) and ciprofloxacin (57%, 42/74)
had activity against a moderate number of isolates. Doxycycline was the least active,
inhibiting only 7% (5/74) of isolates. In conclusion, the variations in susceptibility
within M. abscessus isolates to currently available antimicrobials suggest that the
antimicrobial susceptibilities of any clinically significant M. abscessus isolate be
needed individually. 
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Accepted : 25 June 2007agents against M. abscessus isolates: amikacin (Sigma, St. Louis,
MO, U.S.A.), cefoxitin (Sigma), imipenem (MSD, Seoul,
Korea), tobramycin (Sigma), clarithromycin (Hanmi, Seoul,
Korea), ciprofloxacin (Ildong, Seoul, Korea), moxifloxacin
(Bayer, Seoul, Korea), and doxycycline (Sigma). Minimal
inhibitory concentrations (MICs) of all tested drugs were
determined by the broth microdilution method and inter-
preted according to the guidelines described by the NCCLS
document M24-A in 2003 (12). The MIC of moxifloxacin
for this RGM has not yet been described by the NCCLS. In
its place, we followed the recommendation for aerobic organ-
isms in NCCLS M100-S11 in 2001 (13).
The colonies present on the culture medium were trans-
ferred to 15-mL tubes of 7H9 broth (Becton Dickinson, Pis-
cataway, NJ, U.S.A.) with 0.02% Tween 80 (Junsei Chemi-
cal, Tokyo, Japan). The suspension was mixed vigorously on
a vortex mixer for 15 to 20 sec until the turbidity matched
the density of a 0.5 McFarland standard. The suspension was
then diluted a few times following consideration of the final
inoculum concentrations in the well. Serial 2-fold dilutions
of antimicrobial agents were prepared and added across the
96-well plates (Becton Dickinson). The concentrations of
antimicrobial agents in the wells were determined based on
the NCCLS recommendation (12, 13). The final inoculum
suspension (150  L) was transferred to the wells of a micro-
titer tray containing 150  L of each antimicrobial type and
dilution. The final inoculum concentration was 5×104 CFU/
mL per well. The inoculated tray was covered and incubat-
ed at 30℃ for over 3 days in room air. Endpoint MICs of all
the antimicrobial drugs were read as the first well in which
no growth occurred. Staphylococcus aureus ATCC 29213 and
Mycobacterium peregrinum ATCC 700686 were also used for
quality control purposes. The susceptibility categories of all
antimicrobial agents were determined according to the break-
points recommended by the NCCLS and are presented in
Table 1 (12, 13).
RESULTS
In total, 74 isolates of M. abscessus were tested for antimi-
crobial susceptibility. The results of antimicrobial suscepti-
bility tests are presented in Table 2. Of the parenteral antibi-
otics, amikacin (99%, 73/74) and cefoxitin (99%, 73/74) were
active against most M. abscessus isolates. Amikacin demon-
strated better in vitro activity against M. abscessus than tobra-
mycin (36%, 27/74). Imipenem (55%, 36/74) had in vitro
activity against a moderate number of isolates. Of the oral
antibiotics, clarithromycin (91%, 67/74) was active against
the majority of isolates. The fluoroquinolones showed moder-
ate in vitro activities against the M. abscessus isolates. Moxi-
floxacin (73%, 54/74) had better in vitro activity than cip-
rofloxacin (57%, 42/74). Doxycycline was the least active,
inhibiting only 7% (5/74) of the M. abscessus isolates.
DISCUSSION
M. abscessus isolates have been determined to be uniformly
resistant to standard antituberculous agents. For pulmonary
diseases caused by M. abscessus, it is recommended that sus-
ceptible oral antibiotics (including clarithromycin or azithro-
mycin) be administered in combination with parenteral med-
ications (amikacin, cefoxitin, or imipenem) (1, 2). Due to its
variable in vitro susceptibilities to some drugs, antibiotic sus-
ceptibility testing of all clinically significant isolates is rec-
ommended, although the correlation between in vitro suscep-
tibility results for M. abscessus and clinical response for specific
antimicrobial agents has not been established (1, 2). Our
results in this study demonstrated that the resistance rates of
M. abscessus isolates to various antibiotics are high. However,
amikacin and cefoxitin were active against nearly all M. absces-
sus isolates. Clarithromycin was generally active against the
majority of the M. abscessus isolates. In addition, ciprofoxacin,
moxifloxacin, and imipenem exhibited moderate activity
(>50% susceptibility), but the susceptibility of M. abscessus
to doxycyline was poor.
Aminoglycosides are important parenteral antibiotics
used in the treatment of M. abscessus infection. Traditionally,
amikacin was the most active agent against RGM species.
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MIC, minimal inhibitory concentration.
Drugs and breakpoints are listed according to the recommendations
set forth by the NCCLS document M24-A (12). 
*The breakpoints of this antimicrobial agent for the RGM have not yet
been addressed by the NCCLS. The values are those recommended
for aerobic organisms in NCCLS M100-S11 (13).
Suggested breakpoints
S
Drug
IR
Amikacin ≤16 32 ≥64
Cefoxitin ≤16 32-64 ≥128
Imipenem ≤48 ≥16
Tobramycin ≤48 ≥16
Clarithromycin ≤24 ≥8
Ciprofloxacin ≤12 ≥4
Moxifloxacin* ≤12 ≥4
Doxycycline ≤1 2-8 ≥16
Table 1. Antimicrobial drugs and MIC breakpoints
No. (%) of isolates
Susceptible
Drug No.
Intermediate Resistant
Amikacin  74 73 (99) 1 (1) 0 (0)
Cefoxitin 74 73 (99) 1 (1) 0 (0)
Imipenem 66 36 (55) 22 (33) 8 (12)
Tobramycin 74 27 (36) 25 (34) 22 (30)
Clarithromycin 74 67 (91) 5 (7) 2 (3)
Ciprofloxacin  74 42 (57) 19 (26) 13 (18)
Moxifloxacin  74 54 (73) 15 (20) 5 (7)
Doxycycline  74 5 (7) 9 (12) 60 (81)
Table 2. In vitro susceptibility of M. abscessus isolatesAccording to a study by Swenson et al., 95% of M. abscessus,
99% of M. fortuitum, and 88% of M. chelonae isolates were
inhibited by this agent with a MIC of ≤16  g/mL (5). Intra-
venous amikacin is administered at a dose of 10 to 15 mg/
kg daily to adult patients with normal renal function. This
dose elicits peak serum levels in the low 20 mg/mL range.
In this study, 99% of M. abscessus isolates were susceptible
to amikacin and 36% were susceptible to tobramycin.
Cefoxitin is another important parenteral antibiotic used in
the treatment of M. abscessus infection. This agent is admin-
istered at a dose of up to 12 g/day intravenously in divided
doses. In this study, cefoxitin inhibited the growth of 99%
of M. abscessus isolates. Another parenteral antibiotic that has
been used in M. abscessus infection is imipenem. This agent
has been reported to be moderately susceptible against M.
abscessus (14). This study demonstrated that imipenem inhibits
55% of M. abscessus isolates at the breakpoint of <8  g/mL
and 88% of isolates at the intermediate breakpoint of <16
g/mL. Therefore, imipenem may be useful in clinical treat-
ment regimens for M. abscessus, especially in situations when
cefoxitin cannot be used due to adverse effects. 
Of the variable oral antibiotics, the most effective agents
are the newer macrolides. Clarithromycin is representative
of this class and has been considered to be the most effective
(12). In this study, 91% of M. abscessus isolates were suscep-
tible and 3% were resistant to clarithromycin. Brown et al.
reported that the newer macrolides generally show better
activity against RGM species, and among them, clarithro-
mycin is the strongest (15). 
Oral fluoroquinolones have also been used in the treatment
of RGM diseases. Ciprofloxacin is the class representative of
the older fluoroquinolones (i.e., ciprofloxacin, ofloxacin, and
levofloxacin). In the current study, we tested ciprofloxacin
and moxifloxacin (newer 8-methoxyfluoroquinolone), and
both antimicrobials showed high activities, with 57 and
73%, respectively, of M. abscessus isolates susceptible. Even
though fluoroquinolone cannot be used as a single-drug
therapy due to the risk of developing mutational resistance
(16), both ciprofloxacin and moxifloxacin could be used as
alternative oral agents during combination treatment for M.
abscessus lung disease. Doxycycline is a member of the tetra-
cycline antibiotics and has shown poor activity against M.
abscessus and M. chelonae in previous studies. In the current
study, only 21% of M. abscessus isolates were susceptible or
intermediate and approximately 80% were resistant to this
agent. Doxycycline was the least active agent among all those
tested in this study. 
In this study, NTM species identification was performed
using the PCR-RFLP method based on the rpoB gene. RGM
are difficult to speciate by conventional methods. Several
genes such as 16S rRNA, hsp65, and rpoB gene have been
used to identify NTM to the species level. However, some
gene target is often limited by the lack of sequence diver-
gence among closely related Mycobacterium species. For exam-
ple, 16S rRNA internal transcribed spacer assay cannot differ-
entiate M. abscessus from M. massiliense or M. bolletii, although
this assay has proven to be valuable to distinguish M. absces-
sus and M. chelonae (17). Accurate identification of isolated
NTM species is important since distinguishing these species
is clinically relevant.
In conclusion, the variations in susceptibility within M.
abscessus isolates to currently available antimicrobials suggest
that the antimicrobial susceptibility testing of all clinically
significant M. abscessus isolates be needed. In addition, our
results offer clinicians choices for empirical treatment when
M. abscessus lung disease is diagnosed and the in vitro suscep-
tibilities are not available. 
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